Eprex lowers cancer patients' transfusion rates
Eprex lowers cancer patients transfusion rates
Ortho Biotech, a division of Janssen-Cilag, has demonstrated that Eprex (epoetin alpha) safely and effectively reduces blood transfusion rates in patients with hematologic malignancies receiving non-platinum chemotherapy. The study also indicated that Eprex was associated with increased hemoglobin levels and improved quality of life. The median survival in the Eprex-treated group was 17 months, compared to 11 months for patients receiving placebo, suggesting a possible relationship between increased hemoglobin levels and survival. However, the mechanism behind this is not yet clear. Based on the findings of this trial, Eprex has received approval for the use with non-platinum chemotherapy treatments for solid tumors, malignant lymphomas and multiple myeloma.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze